Table 3.
ELN 2017, MRC, AGR, SAMLS, and albumin survival and comparative accuracy
| FMUSP (N = 167) | FMRP (N = 145) | OUH (N = 157) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1-y OS, % | 5-y OS, % | P* | AUC | 1-y OS, % | 5-y OS, % | P* | AUC | 1-y OS, % | 5-y OS, % | P* | AUC | |
| ELN2017 (N = FMUSP) | ||||||||||||
| Favorable (N = 49) | 71 (60-85) | 43 (30-62) | <.001 | 0.68 (0.58-0.77) | — | — | — | — | — | — | — | — |
| Intermediate (N = 34) | 28 (16-48) | 21 (11-41) | — | — | — | — | ||||||
| Adverse (N = 49) | 31 (21-48) | 10 (3-26) | — | — | — | — | ||||||
| MRC (N = FMUSP/FMRP/OUH) | ||||||||||||
| Favorable (N = 23/30/11) | 87 (74-100) | 52 (34-80) | <.001 | 0.63 (0.56-0.71) | 60 (45-80) | 42 (28-65) | .2 | 0.54 (0.45-0.63) | 100 (100-100) | 54 (32-93) | .17 | 0.57 (0.49-0.66) |
| Intermediate (N = 97/80/76) | 49 (40-60) | 29 (20-40) | 46 (36-59) | 25 (16-39) | 79 (70-88) | 49 (40-63) | ||||||
| Adverse (N = 28/16/22) | 25 (13-47) | 10 (3-35) | 54 (33-86) | 20 (7-63) | 59 (42-84) | 34 (19-62) | ||||||
| AGR (N = FMUSP/FMRP/OUH) | ||||||||||||
| Favorable (N = 44/48/28) | 75 (63-89) | 46 (32-66) | <.001 | 0.66 (0.58-0.74) | 60 (48-76) | 43 (31-61) | .04 | 0.59 (0.50-0.69) | 92 (83-100) | 57 (41-80) | .01 | 0.63 (0.55-0.72) |
| Intermediate (N = 85/58/72) | 48 (38-59) | 28 (20-41) | 52 (40-67) | 22 (11-41) | 79 (70-89) | 52 (42-66) | ||||||
| Adverse (N = 36/33/38) | 28 (16-47) | 11 (4-30) | 37 (22-59) | 15 (6-39) | 63 (49-80) | 28 (16-49) | ||||||
| SAMLS (N = FMUSP/FMRP/OUH) | ||||||||||||
| LR AML (N = 63/37/68) | 81 (71-91) | 55 (43-71) | <.001 | 0.80 (0.73-0.88) | 67 (53-84) | 37 (23-60) | .001 | 0.74 (0.63-0.84) | 94 (88-100) | 70 (59-82) | <.001 | 0.77 (0.69-0.86) |
| HR AML (N = 91/57/46) | 26 (18-37) | 9 (4-18) | 35 (24-50) | 14 (7-28) | 60 (47-76) | 28 (17-46) | ||||||
| Albumin (N = FMUSP/FMRP/OUH) | ||||||||||||
| Above 3.8g/dL (N = 61/38/100) | 65 (54-78) | 41 (29-57) | <.001 | — | 73 (60-89) | 44 (30-65) | <.001 | — | 88 (82-94) | 64 (54-75) | <.001 | — |
| Below 3.8g/dL (N = 94/61/27) | 37 (28-48) | 18 (11-28) | 35 (25-50) | 13 (6-28) | 54 (38-77) | 39 (24-63) | ||||||
| 1-y DFS, % | 5-y DFS, % | P* | AUC | 1-y DFS, % | 5-y DFS, % | P* | AUC | 1-y DFS, % | 5-y DFS, % | P* | AUC | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELN 2017 (N = FMUSP) | ||||||||||||
| Favorable (N = 46) | 54 (42-71) | 44 (31-61) | .001 | 0.66 (0.56-0.77) | — | — | — | — | — | — | — | — |
| Intermediate (N = 25) | 29 (16-54) | 21 (10-45) | — | — | — | — | ||||||
| Adverse (N = 29) | 31 (18-55) | 9 (3-33) | — | — | — | — | ||||||
| MRC (N = FMUSP/FMRP/OUH) | ||||||||||||
| Favorable (N = 22/17/11) | 68 (51-90) | 58 (40-83) | .004 | 0.62 (0.53-0.71) | 41 (23-72) | 41 (23-73) | .35 | 0.54 (0.41-0.67) | 82 (62-100) | 36 (17-80) | .9 | 0.51 (0.42-0.60) |
| Intermediate (N = 75/36/73) | 45 (35-58) | 27 (18-41) | 59 (44-79) | 40 (26-63) | 68 (58-80) | 37 (27-51) | ||||||
| Adverse (N = 15/12/16) | 26 (11-61) | 18 (6-56) | 28 (11-73) | 15 (3-76) | 62 (43-91) | 30 (14-65) | ||||||
| AGR (N = FMUSP/FMRP/OUH) | ||||||||||||
| Favorable (N = 41/27/28) | 58 (45-76) | 47 (34-66) | .002 | 0.64 (0.55-0.73) | 54 (38-77) | 50 (34-73) | .04 | 0.60 (0.48-0.66) | 85 (73-100) | 35 (21-60) | .2 | 0.56 (0.47-0.65) |
| Intermediate (N = 63/31/68) | 46 (35-61) | 28 (18-42) | 59 (43-81) | 23 (9-63) | 68 (55-78) | 40 (30-54) | ||||||
| Adverse (N = 21/16/32) | 28 (14-56) | 11 (3-41) | 20 (8-56) | 13 (4-49) | 53 (38-73) | 23 (12-45) | ||||||
| SAMLS (N = FMUSP/FMRP/OUH) | ||||||||||||
| LR AML (N = 60/32/67) | 62 (50-76) | 48 (36-63) | <.001 | 0.70 (0.60-0.79) | 57 (42-78) | 34 (23-58) | .02 | 0.67 (0.54-0.80) | 83 (75-93) | 49 (38-63) | <.001 | 0.65 (0.55-0.75) |
| HR AML (N = 56/36/42) | 28 (18-42) | 13 (7-27) | 31 (19-52) | 9 (2-44) | 49 (36-67) | 20 (11-39) |
The numbers between parentheses represent the 95% CIs.
*
P value as calculated using log-rank test.